US Patent No: 4,844,910

Number of patents in Portfolio can not be more than 2000

Spheroids

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A controlled release pharmaceutical composition comprising a plurality of film coated spheroids, the film coated spheroids comprising a 3-alkylxanthine, a non-water soluble spheronising agent and between 4% and 9% (by weight) water, wherein the in-vitro dissolution rate of the 3-alkylxanthine from the film coated spheroids, when measured by the USP Paddle Method at 100 rpm in 900 ml aqueous buffer (pH 6.5 at 37.degree. C.) is between 7.5% and 25.0% (by wt) release after 1 hour, between 22.5% and 45.0% (by wt) release after 2 hours, between 40.0% and 60.0% (by wt) release after 3 hours, between 50.0% and 75.0% (by wt) release after 4 hours, between 70.0% and 92.5% (by wt) release after 6 hours, and between 80.0% and 100.0% (by wt) release after 8 hours. Preferably the water content is between 4% and 8%, especially between 4% and 7% (by wt) of the film coated spheroid formulation. The preferred 3-alkylxanthine is theophylline (anhydrous or hydrate), whilst the preferred spheronising agent is microcrystalline cellulose.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
EURO-CELTIQUE S.A.LUXEMBOURG87
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURGSTAMFORD, CT0

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Leslie, Stewart T Cambridge, GB3 24 1969
Malkowska, Sandra T A Landbeach, GB3 17 1688
Marchant, Joanne St. Ives, GB3 2 71
Neale, Philip J Harston, GB3 7 855

Cited Art Landscape

Patent Info (Count) # Cites Year
 
EGYT GYOGYSZERVEGYESZETI GYAR, 30-38, KERESZTURI UT, H-1106 BUDAPEST, HUNGARY (1)
* 4,748,023 Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content 48 1984
 
Key Pharmaceuticals, Incorporated (1)
* 4,587,118 Dry sustained release theophylline oral formulation 60 1984
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (4)
* 2005/0192,309 Method of preventing abuse of opioid dosage forms 29 2003
* 2005/0181,046 Tamper-resistant oral opioid agonist formulations 48 2003
* 2005/0095,291 Tamper-resistant oral opioid agonist formulations 59 2003
* 2004/0092,542 Tamper-resistant oral opioid agonist formulations 48 2003
 
PHILIP MORRIS USA INC. (2)
7,866,324 Cigarette and filter with cellulosic flavor addition 0 2006
* 2006/0272,662 Cigarette and filter with cellulosic flavor addition 14 2006
 
EURO-CELTIQUE S.A. (1)
* 5,091,189 Controlled release dosage forms having a defined water content 56 1991
 
PURDUE PHARMA L.P. (49)
6,696,088 Tamper-resistant oral opioid agonist formulations 143 2001
7,943,173 Pharmaceutical combinations of oxycodone and naloxone 4 2002
7,914,818 Opioid agonist formulations with releasable and sequestered antagonist 9 2002
* 2003/0157,168 Sequestered antagonist formulations 64 2002
6,696,066 Opioid agonist/antagonist combinations 143 2002
7,842,311 Tamper-resistant oral opioid agonist formulations 9 2003
* 2004/0186,121 Tamper-resistant oral opioid agonist formulations 55 2003
7,172,767 Opioid agonist / antagonist combinations 89 2003
* 2004/0086,561 Opioid agonist / antagonist combinations 0 2003
7,842,309 Tamper-resistant oral opioid agonist formulations 8 2003
7,718,192 Tamper-resistant oral opioid agonist formulations 17 2003
7,682,632 Tamper-resistant oral opioid agonist formulations 17 2003
7,658,939 Tamper-resistant oral opioid agonist formulations 42 2003
* 2008/0306,104 TAMPER-RESISTANT ORAL OPIOID AGONIST FORMULATIONS 5 2003
9,149,436 Pharmaceutical product comprising a sequestered agent 0 2004
7,384,653 Oral dosage form comprising a therapeutic agent and an adverse-effect agent 26 2004
8,518,925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 6 2005
8,465,774 Sequestered antagonist formulations 5 2006
* 2008/0167,533 Method and Device for the Assessment of Bowel Function 2 2006
7,419,686 Opioid agonist/antagonist combinations 55 2006
* 2007/0122,348 Opioid agonist/antagonist combinations 24 2006
7,749,542 Opioid agonist/antagonist combinations 31 2008
9,271,940 Immediate release pharmaceutical compositions comprising oxycodone and naloxone 0 2010
8,105,631 Opioid agonist/antagonist combinations 30 2010
8,236,351 Tamper-resistant oral opioid agonist formulations 4 2010
8,231,901 Opioid agonist formulations with releasable and sequestered antagonist 1 2011
8,673,355 Opioid agonist/antagonist combinations 9 2011
8,846,090 Matrix for sustained, invariant and independent release of active compounds 9 2012
8,518,443 Opioid agonist formulations with releasable and sequestered antagonist 3 2012
8,357,399 Tamper-resistant oral opioid agonist formulations 2 2012
8,822,487 Opioid agonist/opioid antagonist/acetaminophen combinations 9 2012
8,586,088 Tamper-resistant oral opioid agonist formulations 1 2012
8,758,825 Sequestered antagonist formulations 0 2013
8,815,287 Opiod agonist formulations with releasable and sequestered antagonist 0 2013
8,936,812 Tamper-resistant oral opioid agonist formulations 0 2013
8,846,091 Matrix for sustained, invariant and independent release of active compounds 9 2013
RE45822 Oral dosage form comprising a therapeutic agent and an adverse-effect agent 0 2013
9,084,729 Abuse-resistant controlled-release opioid dosage form 2 2013
8,969,369 Abuse-resistant controlled-release opioid dosage form 11 2013
9,056,051 Abuse-resistant controlled-release opioid dosage form 4 2014
9,205,082 Opioid agonist/antagonist combinations 0 2014
8,932,630 Opioid agonist/antagonist combinations 2 2014
9,278,073 Tamper-resistant oral opioid agonist formulations 0 2015
9,168,252 Abuse-resistant controlled-release opioid dosage form 2 2015
9,161,937 Abuse-resistant controlled-release opioid dosage form 2 2015
9,283,216 Abuse-resistant controlled-release opioid dosage form 0 2015
9,283,221 Abuse-resistant controlled-release opioid dosage form 0 2015
9,358,230 Abuse-resistant controlled-release opioid dosage form 0 2016
9,345,701 Abuse-resistant controlled-release opioid dosage form 0 2016
 
IPSEN PHARMA S.A.S. (2)
* 5,213,812 Preparation process of sustained release compositions and the compositions thus obtained 26 1991
* 5,569,467 Process for the preparation of microballs and microballs thus obtained 16 1994
 
WYETH HOLDINGS LLC (1)
* 5,776,489 Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form 12 1992
 
PFIZER INC. (1)
7,682,634 Pharmaceutical compositions 6 2009
 
ALPHARMA PHARMACEUTICALS, LLC (7)
8,158,156 Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist 0 2007
8,623,418 Pharmaceutical composition 0 2008
7,682,633 Pharmaceutical composition 14 2009
8,877,247 Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist 0 2010
8,685,443 Sequestering subunit and related compositions and methods 0 2010
8,685,444 Sequestering subunit and related compositions and methods 0 2010
8,846,104 Pharmaceutical compositions for the deterrence and/or prevention of abuse 0 2012
 
ROCHE DIABETES CARE, INC. (1)
* 5,413,690 Potentiometric biosensor and the method of its use 346 1993
 
NORDMARK ARZNEIMITTEL GMBH & CO. KG (1)
* 5,160,469 Manufacture of pellets of xanthine derivatives 2 1990
 
ELITE LABORATORIES INC. (3)
8,182,836 Abuse-resistant oral dosage forms and method of use thereof 8 2009
8,425,933 Abuse-resistant oral dosage forms and method of use thereof 7 2009
8,703,186 Abuse-resistant oral dosage forms and method of use thereof 0 2013
 
TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
* 5,945,125 Controlled release tablet 65 1996
 
F.H. FAULDING & CO. LIMITED (1)
* 5,196,203 Theophylline dosage form 56 1991
 
ABBOTT LABORATORIES (1)
* 5,160,742 System for delivering an active substance for sustained release 39 1991
 
AMERICAN CYANAMID COMPANY (1)
* 5,283,065 Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form 101 1992
 
LG DISPLAY CO., LTD. (1)
* 2005/0099,572 Liquid crystal display device 0 2003
* Cited By Examiner